Abstract
Aim: The aim of our study was to investigate whether the administration of rosiglitazone affects bone metabolism and risk of fracture in patients with T2D. Methods: We have investigated 23 patients (9 males and 14 females) with T2D from age 38 to age 51. Patients were divided in two groups: in group I patients previously treated with diet alone were included, in group II — patients who received medications of sulfanilurea. Patients in both groups were prescribed to rosiglitazone 2 mg/d for 20 weeks. We measured HbA1c, fasting and postprandial glucose, ionized calcium (Ca), phosphorus values, parathyroid hormone (PTH), osteocalcin (OC). Bone mineral density was measured by dual-energy X-ray absorptiometry. Results: Rosiglitazone treatment was followed by decreased levels of OC (7.2±0.2 ng/ml, p<0.01). We have not revealed significant changes in bonemineral density in patients treatedwith rosiglitazone. There were no significant changes in levels of Ca (from 1.18± 0.01 mmol/l to 1.09±0.01 mmol/l) and PTH (from 38.3±0.01 pg/ml to 41.7±0.01 pg/ml). Conclusion: Rosiglitazone treatment was followed by decreased level of bone turnover. Conflict of interest: None declared.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
